Strategic partnership between Wyss Zurich RMTP and ZüriPharm AG to promote innovative therapies

The Wyss Zurich Regenerative Medicine Technologies Platform (Wyss Zurich RMTP) of the University of Zurich and ZüriPharm AG have entered into a strategic partnership to support and accelerate the translation of innovative therapies from research to clinical application. The aim of the close collaboration is to cover the entire life cycle of drugs – from preclinical research to clinical trials and standard care.

Wyss Zurich RMTP brings extensive expertise in the development and manufacture of investigational medicinal products in small batches for early clinical trials. With its GMP-certified infrastructure and its focus on innovative technologies such as cell and gene therapies, the platform creates the basis for the transfer of research results into a regulated environment. ZüriPharm AG, with its modern GMP production facilities, complements these competencies with a focus on industrial pharmaceutical production, galenic development and technology transfer for larger production volumes.The cooperation not only enables the efficient use of existing resources and infrastructure, but also offers start-ups and academic researchers an ideal platform to implement their projects with minimal investment. Researchers and patients benefit equally, so that promising therapies become available more quickly.

Together, Wyss Zurich RMTP and ZüriPharm AG are strengthening Zurich’s position as a leading innovation location and creating a forward-looking platform that covers all the necessary steps from the idea in the laboratory to the therapy at the patient’s bedside.